FDA, Merck, and Vioxx: Putting Patient Safety First? : Hearing Before the Committee on Finance, United States Senate, One Hundred Eighth Congress, Second Session, November 18, 2004 - GOVPUB-Y4_F49-PURL-LPS75299 | Content Details | GovInfo

Skip to main content

Start of main content

FDA, Merck, and Vioxx: Putting Patient Safety First? : Hearing Before the Committee on Finance, United States Senate, One Hundred Eighth Congress, Second Session, November 18, 2004

Summary

Branch: Legislative

Category: Congressional Committee Materials

SuDoc Class Number: Y 4.F 49:S.HRG.108-791

Government Author: Congress, Senate, Committee on Finance (Senate)

Series Title: S. hrg. ; 109-791

Publication Title: FDA, Merck, and Vioxx: Putting Patient Safety First? : Hearing Before the Committee on Finance, United States Senate, One Hundred Eighth Congress, Second Session, November 18, 2004

Date Issued: 2005

Subject: Corrupt practices
Drug monitoring
Drugs
Rofecoxib
Testing
United States

Content Origin: This content was harvested from online sources of the original hosting or authoring agency and may not reflect current policy. As Federal agencies add publications to their websites, or report new publications to GPO per statutory mandate (44 U.S.C. §§ 1710, 1902-1903), GPO ensures long-term preservation of and access to the content.